View in EDS

Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial.

Saved in:
Bibliographic Details
Title: Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial.
Authors: Salomão MDG; Centro de Ensaios Clínicos e Farmacovigilância, Instituto Butantan, Av. Vital Brasil, 1500, Butantã, São Paulo, SP 05503-900, Brazil. Electronic address: maria.salomao@fundacaobutantan.org.br., de Almeida Leitão Curimbaba C; Centro de Ensaios Clínicos e Farmacovigilância, Instituto Butantan, Av. Vital Brasil, 1500, Butantã, São Paulo, SP 05503-900, Brazil. Electronic address: caroline.curimbaba@fundacaobutantan.org.br., Braga PE; Centro de Ensaios Clínicos e Farmacovigilância, Instituto Butantan, Av. Vital Brasil, 1500, Butantã, São Paulo, SP 05503-900, Brazil. Electronic address: patricia.braga@fundacaobutantan.org.br., França JID; Centro de Ensaios Clínicos e Farmacovigilância, Instituto Butantan, Av. Vital Brasil, 1500, Butantã, São Paulo, SP 05503-900, Brazil. Electronic address: joao.franca@fundacaobutantan.org.br., Patino EG; Centro de Ensaios Clínicos e Farmacovigilância, Instituto Butantan, Av. Vital Brasil, 1500, Butantã, São Paulo, SP 05503-900, Brazil. Electronic address: Elizabeth.patino@fundacaobutantan.org.br., Boulos FC; Centro de Ensaios Clínicos e Farmacovigilância, Instituto Butantan, Av. Vital Brasil, 1500, Butantã, São Paulo, SP 05503-900, Brazil. Electronic address: fernanda.boulos@fundacaobutantan.org.br., de Sousa Moreira JA; Centro de Ensaios Clínicos e Farmacovigilância, Instituto Butantan, Av. Vital Brasil, 1500, Butantã, São Paulo, SP 05503-900, Brazil. Electronic address: jose.amoreira@fundacaobutantan.org.br.
Corporate Authors: PROFISCOV Study Group; Centro de Ensaios Clínicos e Farmacovigilância, Instituto Butantan, Av. Vital Brasil, 1500, Butantã, São Paulo, SP 05503-900, Brazil.
Source: Vaccine [Vaccine] 2025 Aug 30; Vol. 62, pp. 127527. Date of Electronic Publication: 2025 Jul 28.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2025.127527